Change in BCVA study eye (SE) entire cohort, and categorisation by whether SE is ‘better’ or ‘worse’ relative to fellow eye in terms of letters at baseline*
| N included | Mean 1 | Mean 2 | Mean difference | 95% CI | P value | |
| All study eyes | ||||||
| Change baseline—M12 | 100 | 63.2 | 68.1 | 4.9 | 2.9 to 7.0 | <0.001 |
| Change baseline—M18 | 104 | 62.9 | 69.6 | 6.7 | 4.4 to 9.1 | <0.001 |
| Study eye is ‘better’ eye | ||||||
| Change baseline—M12 | 30 | 64.8 | 68.5 | 3.7 | 1.4 to 6.0 | 0.002 |
| Change baseline—M18 | 32 | 65.1 | 68.2 | 3.1 | −0.8 to 7.1 | 0.118 |
| Study eye is ‘worse’ eye | ||||||
| Change baseline—M12 | 70 | 62.5 | 68.0 | 5.4 | 2.6 to 8.2 | <0.001 |
| Change baseline—M18 | 72 | 62.0 | 70.1 | 8.3 | 5.5 to 11.2 | <0.001 |
*RELIGHT protocol stated that if both eyes are eligible, the one with the worse visual acuity, as assessed at visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment.
BCVA, best-corrected visual acuity.